📚

    The Pathology Comic — Free Preview Panels

    Real panels from eLearning FRCPath's own comic book — "What You Are Not Reading & Nobody Is Teaching You." 70 high-yield points across 10 organ systems, by Dr. Maitrayee Roy and Dr. Akshay Bali. One testable fact per panel. Here's a deep look at every chapter.

    Comic-style illustration of a microscope surrounded by pathology slide panels

    Chapter 1 — Bone & Soft Tissue Pathology

    8 panels

    The lesions that look alike under the scope until one marker ruins the disguise.

    Maps to:FRCPath Part 1FRCPath Part 2
    MDM2 is the friend who stops you calling a bland spindle cell lesion benign when it shouldn't be.
    One negative stain and half the class writes "not GCT" on the answer sheet. The other half keeps the marks.
    SATB2 turning up in a jaw tumor is basically running into your dentist at the gym.
    Two staghorn-vessel tumors walk into a lab. Only STAT6 knows which one's which.
    One gene deletion, six different names on the request form. RB1 really does get around.

    → The FRCPath Part 1 course covers the full marker-panel logic behind every one of these.

    Chapter 2 — Skin & Melanocytic Pathology

    4 panels

    Melanoma, Spitz tumors, and the junctions that hold your skin together.

    Maps to:FRCPath Part 2

    Double Feature: Melanoma, Two Ways

    2cm doesn't sound like much until it's the line between a satellite and a metastasis.
    Melanoma racks up more mutations than a first-year's differential list. For once, that's actually good news.
    WHO finally admitted what every dermpath fellow already suspected: sometimes a Spitz lesion just won't pick a side.
    Desmo means duo, hemi means half. Mix that up on exam day and you'll have a blister of your own.

    → Melanocytic lesions are a FRCPath Part 2 staple — the FRCPath Part 2 course is built around exactly this kind of case-based reasoning.

    Chapter 3 — Hematolymphoid Pathology

    4 panels

    Reed-Sternberg cells, popcorn cells, and the markers that tell them apart.

    Maps to:FRCPath Part 1FRCPath Part 2
    Reed-Sternberg cells aren't a merger of two cells. It's one cell that tried to divide, gave up halfway, and got famous anyway.
    BCL-2 isn't on that report for decoration. It's the actual reason the cell refuses to die on schedule.
    T cells finally got their own version of kappa/lambda. Took long enough.
    The actual tumour cells are the ones you can barely find in a sea of reactive lymphocytes. Typical.

    → Practice this directly with the 1200+ pathology MCQ bank

    Chapter 4 — Thoracic & Lung Pathology

    8 panels

    PD-L1, liquid biopsy, and every molecular subtype the lung throws at you.

    Maps to:FRCPath Part 1FRCPath Part 2MD/DNB Pathology
    Mesothelial cells can't fully commit to being epithelial or mesenchymal. Honestly, relatable.
    PD-L1 used to be the whole answer. Now it barely gets half the marks.
    Four transcription factors, four completely different personalities of small cell lung cancer. INSM1 is still the dependable one.
    Synaptophysin and chromogranin both go quiet, and it's still a neuroendocrine tumor. Blame the tuft cells.
    A negative first-line panel isn't the finish line. It's the "please continue" sign.

    → See the complete FRCPath exam guide for how molecular lung pathology weighs into the syllabus.

    Chapter 5 — Cell Biology & Mechanisms of Disease

    5 panels

    How cells actually die, scar, and switch their genes off.

    Maps to:FRCPath Part 1MD/DNB Pathology
    Turns out cells have almost as many ways to die as pathology has ways to test you on it.
    Neutrophils throwing their own DNA out like a net. Great against bacteria, rough on the neighbourhood.
    Trichrome counts how much damage happened. Elastic stain tells you how long ago it started. Together, basically the liver's diary.
    SMARCB1 and SMARCA4 keep EZH2 in check. The second they clock out, EZH2 throws a party nobody invited.

    → Build the base with structured NEET SS notes

    Chapter 6 — Gynecologic Pathology

    12 panels

    Cervix, ovary and endometrium — where the exam loves to get specific.

    Maps to:FRCPath Part 1
    E6 takes out p53, E7 takes out Rb. HPV really came in swinging with a two-for-one deal.

    Pop Quiz: Gynaec Cytology

    "?Invasive SCC" on a cytology report is not a maybe. It's a two-week-wait referral wearing a disguise.
    A negative HPV test just bought her five years off, not five months of worry.
    Detach, clump up, recruit a few fibroblasts as bodyguards. Ovarian cancer cells have an actual survival strategy, and it's a good one.
    5mm is all it takes to flip "borderline" into "call the oncologist."
    APC gets all the textbook fame for colon cancer. PTEN has quietly been running the same show in the endometrium the whole time.
    A proofreading enzyme breaks, mutations pile up, and somehow that mess is why the immune system shows up in force. Cancer biology, everyone.

    → Gynecologic pathology alone can swing your FRCPath Part 1 score — the NEET SS Pathology preparation course dedicates a full module to it.

    Chapter 7 — Genitourinary Pathology: Prostate & Bladder

    7 panels

    Gleason grades, PTEN, and the variants that change management.

    Maps to:NEET-SS PathologyFRCPath Part 1
    Normal prostate cells make citrate and call it a day. Cancer cells flip the switch and start making energy instead. Overachievers.
    Same 5% tumor, two completely different rules depending on which specimen it landed in. The exam loves this exact detail.
    Same cribriform pattern, same ugly nuclei. Only one of them actually broke out of the duct — the basal cells are the bouncers who decide which.
    PTEN is the brake pedal. Lose it, and prostate cancer finds the accelerator.
    One mutation in a promoter region and the cell simply forgets how to grow old. Thyroid and bladder both fall for it.

    → Drill marker-based differentials like these with the pathology board-style practice questions

    Chapter 8 — Renal Pathology: Medical & Neoplastic

    15 panels

    From glomeruli to pediatric renal tumors — for a reason.

    Maps to:NEET-SS PathologyFRCPath Part 2

    The biggest chapter in the book.

    Daughter cysts, hydatid sand, and a gross specimen photo that never fails to make the whole room go quiet.
    Titer drops, patient goes into remission. Titer creeps back up, so does the proteinuria. PLA2R does not do subtlety.
    Nephrin, podocin and CD2AP hold the whole filtration barrier together. Break one, and the protein just walks straight out.

    Side by Side: Congenital Mesoblastic Nephroma

    Same tumor name, two very different personalities. One's chill. The other one keeps coming back.
    Identical under the microscope, same fusion gene, different postcode. Morphology alone would never have caught this.
    Clear, pink, papillary or invasive — the cytoplasm hands you the first clue before molecular testing even opens its mouth.
    Carbonic anhydrase's day job is keeping pH balanced. In renal cell carcinoma, it moonlights as a metastasis enabler.
    Block the hydroxylase, stabilize HIF-1a, and the tumorigenesis switch flips before anyone notices.

    → Renal is where most candidates lose the most marks. Go deeper with the IHC markers reference guide

    Chapter 9 — Gastrointestinal Pathology

    5 panels

    Colon cancer's favorite tricks, and the syndrome you should never miss.

    Maps to:NEET-SS PathologyFRCPath Part 1
    One to four cells breaking off at the invasive front. Small detail, huge difference to the prognosis line of the report.
    Same organ, same word "colorectal," wildly different outcomes depending on which CMS subtype shows up.
    Snail, Slug and ZEB1 sound like a band lineup. They're actually why colon cancer cells learn to let go and invade.
    Colorectal cancer before 50 isn't bad luck until someone proves otherwise. Check for Lynch first.
    Exon 18's D842V mutation shrugs off imatinib like it's nothing. Know this one before the exam does.

    → Test yourself on exactly this reasoning with the free 199 pathology MCQs PDF

    Chapter 10 — Bonus: Immuno-Oncology

    2 panels

    One last high-yield concept, then meet the people behind this book.

    Maps to:FRCPath Part 1FRCPath Part 2NEET-SS Pathology
    More mutations means more neoantigens means more reasons for the immune system to finally notice the tumor.

    → That's the mindset the whole book runs on — one specific, testable point at a time.

    Get the Full Book (Free)

    That's 44 of 70 panels. The rest — including the full Renal and Gynecologic chapters — is free.

    Liked the Panels? Wait Till You See the Courses

    Everything above is a taster from full-length courses at eLearning FRCPath — video lectures, 1,200+ MCQs, high-yield notes, and real whiteboard sessions, taught by practicing pathologists.

    Also explore our structured NEET SS study plan and complete syllabus breakdown.

    Ready to test what you've read? Try our free mock test or free MCQs, or check the best books for NEET SS Pathology for deeper reading.